← board
LSTA
Lisata Therapeutics, Inc.distress 4/10 · elevated risk$2.17-1%today-57% from 52w high
Oncology 1
Lead: metastatic pancreatic ductal adenocarcinoma · target PD-L1 · est. market ~$5B (approx, global)
Revenue
pre-revenue
Liquidity
$13M
Runway
1.0 yrs
Shares 1y
+4%
Price & events
-46.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.4%
1D
-38.0%
1W
-37.5%
1M
-34.8%
3M
-47.2%
6M
-18.1%
1Y
-38.0%
2Y
-89.5%
5Y
-90.0%
All
Overview
- Market Cap
- $19.76M
- Volume
- 4.42K
- 52 Week Range
- $1.86 – $5.04
- Total Shares
- 9.11M
- Float Shares
- 7.20M
- Short %
- 1.39%
- % Held by Insiders
- 20.89%
- % Held by Institutions
- 11.43%
- RVOL
- 0.05x
- Beta
- 0.80
Pipeline stages · 1 programs
certepetide, Durvalumab, CisplatinPD-L1
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-04-05 | Phase 2 | certepetide, Durvalumab, Cisplatinfast trackorphanrare pediatric | Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma, Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, Bile Duct Cancer, Gall Bladder Cancer, Gall Bladder Carcinoma | 66 | terminated |
Catalyst news & presentations · 18
- 2026Guided 40%readoutPhase 2certepetide · Data from Qilu Pharmaceutical's Phase 2 trialSEC 8-K
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- early 2026trial initiationsecondaryPhase 3certepetide · Plan to advance certepetide development to Phase 3 in early 2026SEC 8-K
- first quarter of 2026readoutPhase 1/2certepetide · Final data from iLSTA trialSEC 8-K
- 2026-03-06partnershipcertepetide · Entered into merger agreement with Kuva Labs; shareholders to receive $5.00 per share plus contingent value right of $1.00 upon NDA filing for certepetide.SEC 8-K
- 2026-01-23withdrawalcertepetide · Mutual termination of exclusive license and collaboration agreement with Qilu for Greater ChinaSEC 8-K
- fourth quarter of 2025readoutPhase 2certepetide · Topline data from BOLSTER trialSEC 8-K
- later this yearenrollment completesecondaryPhase 2certepetide · Enrollment completion targeted for later this yearSEC 8-K
- 2025-11-06partnershipStrategic alliance with GATC Health for AI drug discovery platformSEC 8-K
- 2025-11-06partnershipcertepetide · Global license agreement with Catalent for use in ADC technologySEC 8-K
- 2025-07-08fda agreementcertepetide · U.S. Patent No. 12,351,653 issued for composition of matter of certepetide, expiring March 2040.SEC 8-K
- 2 July 2025conferencedata presentationsecondaryPhase 2certepetide · Preliminary Cohort B data from ASCEND trial at ESMO GISEC 8-K
- mid-2025readoutPhase 2certepetide · Topline data readout from BOLSTER trialSEC 8-K
- first half of 2025enrollment completesecondaryPhase 2certepetide · Enrollment completion for second-line CCA cohort in BOLSTERSEC 8-K
- January 2025conferencedata presentationsecondaryPhase 2certepetide · Presentation at ASCO GI 2025SEC 8-K
- fourth quarter of 2024readoutPhase 2certepetide · Topline data from Phase 2b ASCEND trialSEC 8-K
- fourth quarter of 2024trial initiationsecondaryPhase 2certepetide · First patient enrollment in second-line cohort of BOLSTER trialSEC 8-K
- by the end of 2024enrollment completesecondaryPhase 1/2certepetide · Complete enrollment in colon and appendiceal cohorts of CENDIFOXSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-05-15HC Wainwright & Co.Buy → Neutral
- 2026-01-21Brookline CapitalBuy → Hold
- 2025-08-21HC Wainwright & Co.Buy
- 2025-07-15Brookline CapitalBuy
- 2024-12-11HC Wainwright & Co.Buy
- 2024-11-21HC Wainwright & Co.Buy
Competitors — PD-L1
Recent news
- 2026-07-22Lisata Therapeutics Stock Falls After Hours: Here's Why - Benzinga
- 2026-07-21Morning Market Movers: ZYBT, LSTA, WNW, DHR See Big Swings - RTTNews
- 2026-07-21Morning Market Movers: ZYBT, LSTA, WNW, DHR See Big Swings - RTTNews
- 2026-07-21Lisata Therapeutics (LSTA) says Kuva tender meets conditions but financing not yet secured - Stock Titan
- 2026-07-20Lisata Therapeutics (LSTA) Q4 2023 Earnings Report - Results, Call & Slides - TipRanks
- 2026-07-19Enterprise value to EBIT forward of Lisata Therapeutics, Inc. – LSE:0HS8 - TradingView
- 2026-07-19HC Wainwright & Co. downgrades Lisata Therapeutics (LSTA) - MSN
- 2026-07-18LSTA Q3 2025 Earnings: EPS Beat on Narrower-Than-Expected Loss - Earnings Deceleration Risk - dars.gov.et
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.